St. Francis Medical: Staking Ground in Dynamic Stabilization
Spine, one of the device industry's hottest, most fertile segments, has a history of quick adoption and quick retrenchment (read spinal cages) and standards of care that are anything but gold standards. Perhaps the most interesting example of spine's ambivalent attitude toward technology is artificial discs. Artificial discs caught fire a couple of years ago in the US and promised to be the device industry's next blockbuster technology. But before the first-generation discs had even made it to market, spine surgeons-and the companies that develop new technology-were already onto the next big thing: dynamic stabilization devices, which fall somewhere between the motion-preserving qualities of disc replacement and the stabilization that cages offer. Dynamic stabilization devices are too new for their role in treating spine problems to be fully assessed, but a host of companies are already lining up. One of the first: St. Francis Medical Technologies, which after a difficult struggle with the FDA to get its device approved, is ready to take on the US market and test the potential of at least one category of dynamic stabilization devices: interspinous spacer devices.
By David Cassak
In most medical device segments, the promise of new technology lies in its obvious and straightforward efficacy: a new, clearly effective solution to an unmet clinical need or an intuitively...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
